Guoyue Yuan

ORCID: 0000-0003-0822-6066
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Diabetes Treatment and Management
  • Metabolism, Diabetes, and Cancer
  • Lipid metabolism and disorders
  • Adipose Tissue and Metabolism
  • Adipokines, Inflammation, and Metabolic Diseases
  • Diabetes Management and Research
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Liver Disease Diagnosis and Treatment
  • Pancreatic function and diabetes
  • Diabetes and associated disorders
  • Thyroid Disorders and Treatments
  • Regulation of Appetite and Obesity
  • Diet, Metabolism, and Disease
  • Fibroblast Growth Factor Research
  • Growth Hormone and Insulin-like Growth Factors
  • Caveolin-1 and cellular processes
  • Cardiovascular Function and Risk Factors
  • Epigenetics and DNA Methylation
  • Kruppel-like factors research
  • Immune Cell Function and Interaction
  • Peroxisome Proliferator-Activated Receptors
  • Parasites and Host Interactions
  • T-cell and B-cell Immunology
  • Berberine and alkaloids research
  • Cancer, Lipids, and Metabolism

Jiangsu University
2016-2025

Affiliated Hospital of Jiangsu University
2016-2025

GTx (United States)
2013

Shanghai Jiao Tong University
2010

Ruijin Hospital
2005-2008

Glucagon-like peptide-1 (GLP-1) is a 30-amino acid peptide hormone that mainly expressed in the intestine and hypothalamus. In recent years, basic clinical studies have shown GLP-1 closely related to lipid metabolism, it can participate metabolism by inhibiting fat synthesis, promoting differentiation, enhancing cholesterol adipose browning. plays key role occurrence development of metabolic diseases such as obesity, nonalcoholic fatty liver disease, atherosclerosis regulating metabolism. It...

10.4093/dmj.2023.0277 article EN cc-by-nc Diabetes & Metabolism Journal 2024-04-02

Betatrophin, a newly identified hormone, has been recently characterized as potent stimulator that increases the production and expansion of insulin-secreting β-cells in mice, but physiological role betatrophin remains poorly understood. This study measured for first time serum levels diagnosed patients with type 2 diabetes (T2DM) explored correlations between its various metabolic parameters T2DM.We analyzed concentrations by ELISA blood samples 166 well-characterized individuals whom...

10.2337/dc14-0602 article EN Diabetes Care 2014-07-15

Oxytocin can affect energy homeostasis and has interesting potential as a metabolic disease therapeutic. We detected serum oxytocin levels in obese (OB) type 2 diabetes mellitus (T2DM) subjects investigated the relationships between glycolipid metabolism, insulin resistance, pancreatic β-cell function, inflammation.A total of 176 were enrolled study, including 88 patients with newly diagnosed T2DM normal glucose tolerance (NGT). NGT groups divided into normal-weight (NW) OB subgroups....

10.1210/jc.2014-2206 article EN The Journal of Clinical Endocrinology & Metabolism 2014-09-18

Abstract Aim To evaluate the efficacy and safety of once‐weekly subcutaneous semaglutide, a glucagon‐like peptide‐1 (GLP‐1) analogue, versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes (T2D) multiregional clinical trial. Materials Methods In 30‐week, randomized, double‐blind, double‐dummy, active comparator SUSTAIN China trial, 868 adults T2D inadequately controlled on (HbA1c 7.0%‐10.5%) were randomized receive semaglutide 0.5 mg (n = 288), 1.0 290) or 100...

10.1111/dom.14232 article EN cc-by-nc Diabetes Obesity and Metabolism 2020-10-19

Metformin, the first-line therapy for type 2 diabetes (T2D), decreases hepatic glucose production and reduces fasting plasma levels. Dorzagliatin, a dual-acting orally bioavailable glucokinase activator targeting both pancreas liver glucokinase, postprandial in patients with T2D. In this randomized, double-blind, placebo-controlled phase 3 trial, efficacy safety of dorzagliatin as an add-on to metformin were assessed T2D who had inadequate glycemic control using alone. Eligible (n = 767)...

10.1038/s41591-022-01803-5 article EN cc-by Nature Medicine 2022-05-01

GLP-1 receptor agonists (GLP-1RA) have been extensively utilized in the management of body weight individuals with obesity. Circular RNA (circRNA), a class covalently closed molecules, has garnered increasing attention for its potential role pathogenesis However, specific mechanisms through which circRNA contributes to GLP-1RA-induced loss remains elusive. High-throughput sequencing analyzed epididymal adipose tissue from obese mice under high-fat, and GLP-1RA intervention (600 μg/kg/d). The...

10.1016/j.ygeno.2025.110988 article EN cc-by-nc-nd Genomics 2025-01-05

Berberine, a hypoglycemic agent, has recently been shown to activate AMP-activated protein kinase (AMPK) contributing its beneficial metabolic effects in peripheral tissues. However, whether berberine exerts regulatory effect on β-cells via AMPK or other signaling pathways and counteracts glucolipotoxicity remains uncertain. In the present study, impact of β-cell function was investigated vivo vitro. high-fat-fed rats, treatment for 6 wk significantly decreased plasma glucose insulin levels...

10.1210/en.2007-1752 article EN Endocrinology 2008-05-29

Background/aim: Previous studies have suggested that the hepatic steatosis index (HSI) and fatty liver (FLI) can be used as a predictor of non-alcoholic disease (NAFLD).The aim our study was to determine whether non-invasive indices (HSI FLI) are associated with carotid atherosclerosis in type 2 diabetes mellitus (T2DM).Methods: This cross-sectional conducted T2DM patients (n=768).Carotid intima-media thickness (CIMT) measured by Color Doppler ultrasound.The HSI calculated based on gender,...

10.7150/ijms.62010 article EN cc-by-nc International Journal of Medical Sciences 2021-01-01

Abstract Aims/hypothesis The aim of this study was to evaluate the efficacy and safety oral semaglutide monotherapy vs placebo in a predominantly Chinese population with type 2 diabetes insufficiently controlled diet exercise alone. Methods Peptide Innovation for Early Diabetes Treatment (PIONEER) 11 trial double-blind, randomised, Phase IIIa conducted across 52 sites China region (mainland Taiwan), Hungary, Serbia Ukraine. Eligible participants were ≥18 years (≥20 had diagnosis HbA 1c 53–86...

10.1007/s00125-024-06142-3 article EN cc-by Diabetologia 2024-07-10

Hashimoto's thyroiditis (HT) represents the most common organ-specific autoimmune disease. Inflammatory factors and Reactive Oxygen Species (ROS) play detrimental roles during pathogenesis of HT. In this study, we found that thyroid follicular cells (TFCs) from HT patients expressed an elevated level interleukin-23 (IL-23), which contributed to autophagy suppression ROS accumulation. Additionally, IL-23-induced accumulation in human TFCs was attributed AKT/mTOR/NF-κB signalling pathway...

10.3389/fimmu.2018.00096 article EN cc-by Frontiers in Immunology 2018-01-28

Vascular calcification is a significant predictor of coronary heart disease events, stroke, and lower-limb amputation. Advanced glycation end-products (AGEs) play key role in the development vascular calcification. However, Nε-carboxymethyl-lysine (CML), major active ingredient heterogeneous AGEs, atherosclerotic diabetic patients underlying mechanism remain unclear. Hence, CML transmission pathway cascade were investigated present study. In vivo vitro investigations performed. study I, 45...

10.1186/s13098-016-0196-7 article EN cc-by Diabetology & Metabolic Syndrome 2016-12-01

The histone acetyltransferases CREB-binding protein (CBP) and its paralogue p300 are transcriptional coactivators which essential for a multitude of signaling pathways energy homeostasis. However, the role CBP/p300 HAT domain in regulating balance is still unclear. Here, C57BL/6 mice fed with either normal chow diet (NCD) or high-fat (HFD) were administrated A-485, recently reported selective inhibitor activity 1 week metabolic change was analyzed. white adipose tissue (WAT) weight adipocyte...

10.1038/s41419-020-02960-6 article EN cc-by Cell Death and Disease 2020-09-11

To compare the efficacy and safety of iGlarLixi with insulin glargine 100 units/mL (iGlar) lixisenatide (Lixi), in Asian Pacific people suboptimally controlled type 2 diabetes (T2D) on metformin or without a second oral antihyperglycaemic drug (OAD).LixiLan-O-AP (NCT03798054) was 24-week multicentre study adults (n = 878, mean age 56.0 years, body mass index 26.0 kg/m2 ) glycated haemoglobin (HbA1c) levels ≥53 mmol/mol (7%) ≤97 (11%) OAD(s), randomized (2:2:1) to open-label once-daily...

10.1111/dom.14722 article EN cc-by-nc Diabetes Obesity and Metabolism 2022-04-20

C-reactive protein (CRP) is considered as one of the most sensitive markers inflammation. The aim present study to investigate effects CRP on production adiponectin in 3T3-L1 adipocytes. Northern and western blot analysis revealed that treatment inhibited mRNA expression secretion a dose- time-dependent manner. Co-incubation adipocytes with rosiglitazone decreased induction gene by rosiglitazone. However, luciferase reporter assays did not show affected activity approximately 2.1 kb...

10.1677/joe-07-0133 article EN Journal of Endocrinology 2007-07-19
Coming Soon ...